Human CD20 Full-Length Proteins
CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an appropriate CD20 protein on the market for detecting the CD20-CAR expression and the bioactivity of antibody drugs.
To tackle these challenges, ACROBiosystems has designed the full-length multi-transmembrane CD20 proteins, produced by HEK293 cells and insect cells. The bioactivity and purity of the full-length CD20 protein were confirmed by ELISA, SDS-PAGE, and SPR. In addition, ACROBiosystems provides full-length CD20 protein for immunization and assessment of CD20-CAR expression.
.png)
No hay comentarios:
Publicar un comentario